Statins are aromatic cyclic chemical compounds. Statins inhibit cholesterol synthesis by inactivating the enzyme that catalyzes this process, thereby reducing the risk of heart attack and stroke. In recent years, high doses of statins, along with chemotherapies and other combination therapies such as radiation, immunotherapy, radiotherapy, and antioxidant therapies, have proven highly effective in fighting cancer.

The book serves as a bridge between statin-induced biochemical and metabolic transformations, from cholesterol lowering to mitigate apoptosis, proliferation, autophagy, senescence, immune response, and metastasis, as a magical option in cancer prevention. The book presents concepts, the current state of the art, new options for statin-based nanoformulations, CAR–T cell therapy, and statin-in-combination adjunct therapies as potential cancer nanomedicines for researchers, medical professionals, the pharmaceutical industry, and academicians.

The book advocates the concept of “Triple modal statin-in-combination cancer treatment” based on the fact that statins elevate the oxygen utilization and mitigate the cardiovascular damage caused by cancer. The possible ‘triple modal therapies’ include low-dose statins given with chemodrugs, radiation, targeted therapy, and CAR T-cell therapy.

The statins do have a significant influence on sex-dependent mechanisms of cancer prevention in diabetes patients. The testosterone hormone in males and progesterone hormone in females have specific roles in cardiac prevention, reduced cardiac toxicity, and cancer treatment, specifically breast cancer in diabetic females and prostate cancer in males.

The readers will experience the contents in the present book as quick learners with awareness of the inconclusive, controversial, but high-potential statins given to female and male cancer patients with secondary problems of diabetes, old age, drug-resistance, recurrence among patients showing poor patient and clinical outcomes.